Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Retreatment with venetoclax + acalabrutinib after fixed-duration venetoclax in CLL
2019-004337-17Phase 2Active
- Sponsor
- HOVON
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoint: Undetectable minimal residual disease in bone marrow at cycle 26. Started Jun 2020; status: active.
02
Drugs
venetoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-004337-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004337-17.